Increased incidence of symptomatic peripheral neuropathy among adults receiving stavudine-versus zidovudine-based antiretroviral regimens in Kenya

Christine J. McGrath, Julia Njoroge, Grace C. John-Stewart, Pamela K. Kohler, Sarah F. Benki-Nugent, Joan W. Thiga, Anthony Etyang, Michael H. Chung

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The incidence of peripheral neuropathy (PN) among adults initiating antiretroviral therapy (ART) containing stavudine (d4T) versus zidovudine (ZDV) is not well described.We compared 1-year incidence between d4T- and ZDV-based regimens in adults initiating ART in a programmatic setting in Kenya. Of 1,848 adults on ART, 1,579 (85 %) initiated d4Tbased and 269 (15%) initiated ZDV-based regimens. One-year incidence of symptomatic PN per 100 person-years was 21.9 (n0236) among d4T users and 6.9 (n07) among ZDV users (P00.0002). D4T was associated with 2.7 greater risk of PN than ZDV (adjusted hazard ratio, 2.7, P00.009). In settings with continued d4T use, such as Africa, the effects of d4T on PN compared to ZDV should be considered when choosing ART regimens.

Original languageEnglish (US)
Pages (from-to)200-204
Number of pages5
JournalJournal of NeuroVirology
Volume18
Issue number3
DOIs
StatePublished - Jun 2012
Externally publishedYes

Fingerprint

Stavudine
Zidovudine
Kenya
Peripheral Nervous System Diseases
Incidence
Therapeutics

Keywords

  • Africa
  • Antiretroviral therapy
  • HIV
  • Peripheral neuropathy
  • Toxicity

ASJC Scopus subject areas

  • Virology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Neurology

Cite this

McGrath, C. J., Njoroge, J., John-Stewart, G. C., Kohler, P. K., Benki-Nugent, S. F., Thiga, J. W., ... Chung, M. H. (2012). Increased incidence of symptomatic peripheral neuropathy among adults receiving stavudine-versus zidovudine-based antiretroviral regimens in Kenya. Journal of NeuroVirology, 18(3), 200-204. https://doi.org/10.1007/s13365-012-0098-x

Increased incidence of symptomatic peripheral neuropathy among adults receiving stavudine-versus zidovudine-based antiretroviral regimens in Kenya. / McGrath, Christine J.; Njoroge, Julia; John-Stewart, Grace C.; Kohler, Pamela K.; Benki-Nugent, Sarah F.; Thiga, Joan W.; Etyang, Anthony; Chung, Michael H.

In: Journal of NeuroVirology, Vol. 18, No. 3, 06.2012, p. 200-204.

Research output: Contribution to journalArticle

McGrath, CJ, Njoroge, J, John-Stewart, GC, Kohler, PK, Benki-Nugent, SF, Thiga, JW, Etyang, A & Chung, MH 2012, 'Increased incidence of symptomatic peripheral neuropathy among adults receiving stavudine-versus zidovudine-based antiretroviral regimens in Kenya', Journal of NeuroVirology, vol. 18, no. 3, pp. 200-204. https://doi.org/10.1007/s13365-012-0098-x
McGrath, Christine J. ; Njoroge, Julia ; John-Stewart, Grace C. ; Kohler, Pamela K. ; Benki-Nugent, Sarah F. ; Thiga, Joan W. ; Etyang, Anthony ; Chung, Michael H. / Increased incidence of symptomatic peripheral neuropathy among adults receiving stavudine-versus zidovudine-based antiretroviral regimens in Kenya. In: Journal of NeuroVirology. 2012 ; Vol. 18, No. 3. pp. 200-204.
@article{48d77de628924a559a4d58d503d83956,
title = "Increased incidence of symptomatic peripheral neuropathy among adults receiving stavudine-versus zidovudine-based antiretroviral regimens in Kenya",
abstract = "The incidence of peripheral neuropathy (PN) among adults initiating antiretroviral therapy (ART) containing stavudine (d4T) versus zidovudine (ZDV) is not well described.We compared 1-year incidence between d4T- and ZDV-based regimens in adults initiating ART in a programmatic setting in Kenya. Of 1,848 adults on ART, 1,579 (85 {\%}) initiated d4Tbased and 269 (15{\%}) initiated ZDV-based regimens. One-year incidence of symptomatic PN per 100 person-years was 21.9 (n0236) among d4T users and 6.9 (n07) among ZDV users (P00.0002). D4T was associated with 2.7 greater risk of PN than ZDV (adjusted hazard ratio, 2.7, P00.009). In settings with continued d4T use, such as Africa, the effects of d4T on PN compared to ZDV should be considered when choosing ART regimens.",
keywords = "Africa, Antiretroviral therapy, HIV, Peripheral neuropathy, Toxicity",
author = "McGrath, {Christine J.} and Julia Njoroge and John-Stewart, {Grace C.} and Kohler, {Pamela K.} and Benki-Nugent, {Sarah F.} and Thiga, {Joan W.} and Anthony Etyang and Chung, {Michael H.}",
year = "2012",
month = "6",
doi = "10.1007/s13365-012-0098-x",
language = "English (US)",
volume = "18",
pages = "200--204",
journal = "Journal of NeuroVirology",
issn = "1355-0284",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Increased incidence of symptomatic peripheral neuropathy among adults receiving stavudine-versus zidovudine-based antiretroviral regimens in Kenya

AU - McGrath, Christine J.

AU - Njoroge, Julia

AU - John-Stewart, Grace C.

AU - Kohler, Pamela K.

AU - Benki-Nugent, Sarah F.

AU - Thiga, Joan W.

AU - Etyang, Anthony

AU - Chung, Michael H.

PY - 2012/6

Y1 - 2012/6

N2 - The incidence of peripheral neuropathy (PN) among adults initiating antiretroviral therapy (ART) containing stavudine (d4T) versus zidovudine (ZDV) is not well described.We compared 1-year incidence between d4T- and ZDV-based regimens in adults initiating ART in a programmatic setting in Kenya. Of 1,848 adults on ART, 1,579 (85 %) initiated d4Tbased and 269 (15%) initiated ZDV-based regimens. One-year incidence of symptomatic PN per 100 person-years was 21.9 (n0236) among d4T users and 6.9 (n07) among ZDV users (P00.0002). D4T was associated with 2.7 greater risk of PN than ZDV (adjusted hazard ratio, 2.7, P00.009). In settings with continued d4T use, such as Africa, the effects of d4T on PN compared to ZDV should be considered when choosing ART regimens.

AB - The incidence of peripheral neuropathy (PN) among adults initiating antiretroviral therapy (ART) containing stavudine (d4T) versus zidovudine (ZDV) is not well described.We compared 1-year incidence between d4T- and ZDV-based regimens in adults initiating ART in a programmatic setting in Kenya. Of 1,848 adults on ART, 1,579 (85 %) initiated d4Tbased and 269 (15%) initiated ZDV-based regimens. One-year incidence of symptomatic PN per 100 person-years was 21.9 (n0236) among d4T users and 6.9 (n07) among ZDV users (P00.0002). D4T was associated with 2.7 greater risk of PN than ZDV (adjusted hazard ratio, 2.7, P00.009). In settings with continued d4T use, such as Africa, the effects of d4T on PN compared to ZDV should be considered when choosing ART regimens.

KW - Africa

KW - Antiretroviral therapy

KW - HIV

KW - Peripheral neuropathy

KW - Toxicity

UR - http://www.scopus.com/inward/record.url?scp=84863709482&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863709482&partnerID=8YFLogxK

U2 - 10.1007/s13365-012-0098-x

DO - 10.1007/s13365-012-0098-x

M3 - Article

C2 - 22528481

AN - SCOPUS:84863709482

VL - 18

SP - 200

EP - 204

JO - Journal of NeuroVirology

JF - Journal of NeuroVirology

SN - 1355-0284

IS - 3

ER -